HomeCompareBOIRF vs NNN

BOIRF vs NNN: Dividend Comparison 2026

BOIRF yields 4.58% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NNN wins by $799.00 in total portfolio value· pulled ahead in Year 10
10 years
BOIRF
BOIRF
● Live price
4.58%
Share price
$30.00
Annual div
$1.37
5Y div CAGR
-6.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$277.87
Full BOIRF calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — BOIRF vs NNN

📍 NNN pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBOIRFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BOIRF + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BOIRF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BOIRF
Annual income on $10K today (after 15% tax)
$389.02/yr
After 10yr DRIP, annual income (after tax)
$236.19/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, NNN beats the other by $1,993.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BOIRF + NNN for your $10,000?

BOIRF: 50%NNN: 50%
100% NNN50/50100% BOIRF
Portfolio after 10yr
$25.1K
Annual income
$1,450.28/yr
Blended yield
5.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

BOIRF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.4
Piotroski
6/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BOIRF buys
0
NNN buys
2
PoliticianChamberTickerTypeAmountDate
Lisa McClain🏢 House$NNN▼ Sell$1,001 - $15,0002025-08-13
Lisa McClain🏢 House$NNN▲ Buy$1,001 - $15,0002025-06-17
Zoe Lofgren🏢 House$NNN▼ Sell$1,001 - $15,0002023-05-25
Ro Khanna🏢 House$NNN▼ Sell$1,001 - $15,0002022-01-20
Zoe Lofgren🏢 House$NNN▲ Buy$1,001 - $15,0002021-09-30
Zoe Lofgren🏢 House$NNN▼ Sell$1,001 - $15,0002020-03-23
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBOIRFNNN
Forward yield4.58%5.66%
Annual dividend / share$1.37$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-6.9%8.6%
Portfolio after 10y$24.7K$25.5K
Annual income after 10y$277.87$2,622.67
Total dividends collected$3.5K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: BOIRF vs NNN ($10,000, DRIP)

YearBOIRF PortfolioBOIRF Income/yrNNN PortfolioNNN Income/yrGap
1$11,126$426.09$10,735$614.96+$391.00BOIRF
2$12,317$412.48$11,572$708.43+$745.00BOIRF
3$13,577$397.33$12,531$819.53+$1.0KBOIRF
4$14,908$381.06$13,633$952.29+$1.3KBOIRF
5$16,316$364.08$14,909$1,111.84+$1.4KBOIRF
6$17,805$346.69$16,392$1,304.77+$1.4KBOIRF
7$19,380$329.18$18,129$1,539.52+$1.3KBOIRF
8$21,049$311.76$20,173$1,827.08+$876.00BOIRF
9$22,817$294.61$22,597$2,181.81+$220.00BOIRF
10← crossover$24,692$277.87$25,491$2,622.67$799.00NNN

BOIRF vs NNN: Complete Analysis 2026

BOIRFStock

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.

Full BOIRF Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this BOIRF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BOIRF vs SCHDBOIRF vs JEPIBOIRF vs OBOIRF vs KOBOIRF vs MAINBOIRF vs ADCBOIRF vs EPRTBOIRF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.